(Q71585964)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

title

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

L Canobbio

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

A Rubagotti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

L Miglietta

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

D Cannata

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

A Curotto

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

D Amoroso

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

F Boccardo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

publication date

1 January 1995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

Journal of Cancer Research and Clinical Oncology

19 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

page(s)

753-756

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf01213322

19 October 2019

exact match

0 references

cites work

A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-alpha in the treatment of advanced renal cell carcinoma or melanoma

1 reference

12 December 2020

Chemotherapy of renal cell carcinoma: 1983-1989.

1 reference

12 December 2020

Therapeutic options in renal cell carcinoma.

1 reference

12 December 2020

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

1 reference

12 December 2020

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

12 December 2020

Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma

1 reference

12 December 2020

alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients

1 reference

12 December 2020

An assessment of the current use of human interferons in therapy of urological cancers

1 reference

12 December 2020

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

12 December 2020

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

12 December 2020

Renal cell cancer: is there long-term survival advantage from cytokine treatment?

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma

1 reference

12 December 2020

Reporting results of cancer treatment

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2

1 reference

12 December 2020

Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha

1 reference

12 December 2020

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma

1 reference

12 December 2020

NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

1 reference

12 December 2020

Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01213322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7499447%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference